Comparing two blood tests to guide iron treatment in dialysis patients
Part of Blood & lymphatic, Kidney & urinary clinical trials.
This trial tests whether a new blood test (reticulocyte hemoglobin) is better than the usual iron test (transferrin saturation) for guiding when to give iron to people on dialysis. If you have anemia (low red blood cells) from kidney disease, this study may help doctors find the best way to treat your iron levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been on hemodialysis (a machine that cleans your blood) for at least 6 months.
- You have been taking EPO (a medicine to help your body make red blood cells) for at least 6 months.
- Your hemoglobin level (a measure of red blood cells) is lower than 13 g/dL for men or 12 g/dL for women.
- You do not have very high iron levels (ferritin over 800 or TSAT over 40%) in your blood.
- You have not had major bleeding, a blood transfusion, or a recent heart attack or stroke in the past 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a higher or lower dose of iron works better for people on peritoneal dialysis who have low iron levels. It aims to find the best way to treat iron deficiency in this group.
This study looks at blood markers related to iron and other body processes (like minerals, liver function, and inflammation) in people receiving hemodialysis. The results may help doctors better understand what affects health in dialysis patients.
This study is testing a new way to manage anemia (low red blood cells) in people on long-term dialysis. It aims to improve how doctors treat this common issue.
This trial tests if an intravenous iron medication (iron isomaltoside) can improve anemia in patients on peritoneal dialysis. It may help those whose iron levels are low despite stable use of other anemia treatments.
This study tests two medicines (daprodustat and epoetin alfa) to see which one works better for treating low red blood cell counts (anemia) in people with chronic kidney disease who are not on dialysis yet. Both medicines aim to increase hemoglobin and reduce fatigue.
This trial studies whether taking iron by mouth can improve iron levels and anemia (low red blood cell counts) in children with chronic kidney disease. It may help reduce fatigue and support normal blood-making, by comparing different approaches for children who meet specific iron test results.
Hear when a new Hemodialysis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.